Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 0.4% – Here’s Why

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) traded up 0.4% on Friday . The company traded as high as $7.14 and last traded at $7.01. 2,920,923 shares traded hands during trading, a decline of 55% from the average session volume of 6,469,048 shares. The stock had previously closed at $6.98.

Analyst Ratings Changes

RXRX has been the topic of several research reports. Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday, September 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday. Finally, Jefferies Financial Group lowered their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $9.25.

Recursion Pharmaceuticals Trading Down 0.9 %

The company has a 50 day moving average of $6.71 and a two-hundred day moving average of $7.29. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock has a market capitalization of $1.98 billion, a PE ratio of -4.58 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same quarter last year, the business earned ($0.43) EPS. The firm’s revenue for the quarter was up 147.6% compared to the same quarter last year. Sell-side analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $7.00, for a total transaction of $42,000.00. Following the transaction, the chief operating officer now owns 521,138 shares of the company’s stock, valued at approximately $3,647,966. This trade represents a 1.14 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $6.84, for a total value of $78,297.48. Following the completion of the transaction, the director now owns 7,109,875 shares in the company, valued at $48,631,545. The trade was a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 119,235 shares of company stock worth $802,988 over the last ninety days. 15.75% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC bought a new position in Recursion Pharmaceuticals during the third quarter worth about $25,000. Farther Finance Advisors LLC grew its position in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after purchasing an additional 4,091 shares in the last quarter. KBC Group NV lifted its position in Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after acquiring an additional 3,377 shares during the last quarter. Amalgamated Bank raised its position in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares in the last quarter. Finally, San Luis Wealth Advisors LLC bought a new position in shares of Recursion Pharmaceuticals in the 3rd quarter valued at $69,000. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.